BALTIMORE, MD -- (Marketwired) -- 06/04/13 -- Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, notes that key green tea extracts such as Epigallocatechin gallate (EGCG) developed by Plandai Biotechnology Inc. (OTCQB: PLPL), will soon be used to support weight management. Plandai Biotechnology is a developer of highly bioavailable, phytonutrient rich extracts (like EGCG), which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions.
Green tea has long been recognized for its weight management benefits including fat reduction, increased metabolism and improved endurance during exercise. In fact, a recent Pennsylvania State University study featured in Obesity magazine demonstrated that the use of EGCG reduces the ability to absorb fat, thus slowing or reducing the rate of weight gain and also enhances the ability to absorb fat.
Much has been written in recent years regarding the ever-increasing and resulting health consequences stemming from obesity, costing billions of dollars each year. As a result, even the U.S. government has elected to help lead initiatives to reduce obesity. Studies such as the Penn State tests could serve as a driver in the increased consumption of ECGC and other key green tea-based catechins in order to support weight management. The favorable results of this study illustrate how Plandai stands to strongly benefit from its recently announced relationship with Natural Products of South Africa to develop and market a weight management product using Plandai's Phytofare Catechin Complex, and its far-reaching sales potential.
Given that Plandai's products deliver a bioavailability that is superior to other green tea extracts available today, the Company could eventually emerge as a primary source of ECGC via its Phytofare Catechin Complex for use in many weight management products, which represents a revenue opportunity approaching hundreds of millions of dollars worldwide.
Additional detail via the Goldman Small Cap Research article as well as associated disclaimers can be accessed or downloaded in their entirety by visiting www.goldmanresearch.com.
About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap and micro cap stock research reports, daily stock market blogs, and popular investment newsletters. For more information, visit www.goldmanresearch.com.
A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.
About Plandai Biotechnology, Inc. (OTCQB: PLPL): Plandai Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts, which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandai Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing the patented Phytofare extracts in-house allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. Targeted industries for the Company's products include food and beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.
Goldman Small Cap Research
Most Popular Stories
- Networks Vie for U.S. Hispanic TV Viewers
- Ad Counts Rise in 2013 for Hispanic Magazines
- 2014 World Cup Official Noisemakers Quieter than Vuvuzelas
- Saab Gets Back into the Game; U.S. Auto Sales Soar
- Dell Offers Undisclosed Number of Employee Buyouts
- Authorities Close to Deal with JPMorgan Chase over Madoff Response
- Apple Activates Customer-Tracking iBeacon
- 2013 Tech Gift Guide: iPad Mini Still Hot; Chromecast a Great Low-Cost Option
- It's No Yolk: Food-tech Startups Take Aim at Replacing Eggs
- A Biography of Jonathan Ive, Apple's Creative Chief